---
title: "Varegacestat (AL102) in Desmoid tumors: Surgery"
description: "Formulary evidence on Varegacestat (AL102, BMS-986115) in Desmoid tumors: Surgery. Topics: Surgery as second-line treatment for abdominal wall tumors, Resection margins, Surgery compared with observation, Surgery after failure of the surveillance approach, and 8 further topics. 12 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description/surgery"
published: "2026-11-18T22:42:04-05:00"
modified: "2026-11-18T22:42:04-05:00"
---

# Varegacestat (AL102) in Desmoid tumors: Surgery

<a id="heading-2.2.2.1.2"></a>

## 2.2.2.1.2 Surgery

<a id="topic-2.2.2.1.2-1"></a>

### Surgery as second-line treatment for abdominal wall tumors

> “Surgery is the accepted second-line treatment only for sporadic tumour DT located in the abdominal wall failing observation.”
> “For abdominal wall DT, surgery is still the first option in case of progression.”
> “For extremity/girdles/chest wall DT, again surgery should not be the first treatment option unless the expected morbidity is very low (and only following MDT discussion); medical therapy should be administered preferably.”
> “Surgery may still be considered as a second-line treatment for AW tumours as morbidity and risk of recurrence are limited, while other modalities should be preferred for DT located at other sites.”
> “Surgery by surgeons without significant experience in the management of DT is strongly discouraged.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

<a id="topic-2.2.2.1.2-2"></a>

### Resection margins

> “Wide (R0) microscopic margins resection should be the goal, but positive (R1) microscopic margins can be accepted when function or cosmesis is an issue. However, if positive microscopic margins can be anticipated, other managements than surgery should be preferred.”
> “In addition, if R1 resection is obtained in first-line management, there is insufficient evidence to recommend either perioperative radiotherapy or re-operation.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

<a id="topic-2.2.2.1.2-3"></a>

### Surgery compared with observation

> “The results did not show any difference in event-free survival (EFS, 53% versus 58%; p = 0.415) and long-term disease control between patients undergoing surgery and those managed with a conservative approach.”
> “Among patients with unfavorable locations, defined as chest wall, head & neck and upper limb, the 2-year EFS was significantly better in those patients managed non-surgically (52%) compared to those who underwent initial surgery (25%; p = 0.001).”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

<a id="topic-2.2.2.1.2-4"></a>

### Surgery after failure of the surveillance approach

> “Multiple retrospective single institution case series have reported local control rates after complete surgical resection to be ∼80% at 5 years.”
> “When the surveillance approach fails, surgery is still a valid option (IV, A).”

Source: [Kasper et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5834048/)

<a id="topic-2.2.2.1.2-5"></a>

### NCCN and Desmoid Tumor Working Group positions on first-line surgery

> “However, while surgery has historically represented the primary treatment modality for patients with DT, the NCCN Guidelines® and DTWG guidelines no longer support surgery as the first-line option in most situations, given high postsurgical recurrence rates”
> “However, consensus guidance also positions surgery as a primary treatment consideration for patients experiencing complications from sporadic mesenteric DT or for those with non-mesenteric DT that progress despite active surveillance or medical treatment”

Source: [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/)

<a id="topic-2.2.2.1.2-6"></a>

### Indications for surgery and expected recurrence after resection

> “Surgery can be considered as a local therapy option when complete resection with negative margins is technically feasible without undue morbidity and in symptomatic patients; however, RT may also be considered as control rates (85%) are similar to surgery (77-94%).”
> “If R0 margins are achieved the patient should be observed.”
> “Note that a recurrence up to 25% is expected with a median time to recurrence of 16-22mo.”

Source: [Alberta Health Services clinical practice guideline SAR-004 (2025)](https://www.ahs.ca/assets/info/hp/cancer/if-hp-cancer-guide-sar004-desmoid.pdf)

<a id="topic-2.2.2.1.2-7"></a>

### Surgical morbidity, postsurgical recurrence, and the criterion of tumors not amenable to surgery or radiotherapy

> “Surgery used to be the mainstay of treatment; however, due to high morbidity and postsurgical recurrence rates of up to 50% to 88%, it is used less frequently.”
> “The desmoid tumors are not amenable to surgery or radiotherapy; AND”

Source: [Cigna nirogacestat coverage policy (2025)](https://static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_832_coveragepositioncriteria_oncology_ogsiveo_pa.pdf)

<a id="topic-2.2.2.1.2-8"></a>

### Prospective cohort of 771 cases: surgery compared with wait-and-see

> “We conducted a prospective study of 771 confirmed cases of DTF.”
> “Overall, the 2-year EFS was 56%; this value did not differ between patients undergoing an operation and those managed by the wait-and-see approach (53% versus 58%, p = 0.415).”
> “Among patients with favourable locations, the 2-year EFS was similar in patients treated by both surgery (70%) and the wait-and-see approach (63%; p = 0.413). Among patients with unfavourable locations, the 2-year EFS was significantly enhanced in patients initially managed with the wait-and-see approach (52%) compared with those who underwent initial surgery (25%; p = 0.001).”

Source: [Penel et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28735069/)

<a id="topic-2.2.2.1.2-9"></a>

### Recurrence after complete gross resection in a single-institution database

> “Patients undergoing resection during 1982-2011 for primary or locally recurrent desmoids were identified from a single-institution prospective database.”
> “Desmoids were treated surgically in 495 patients (median follow-up 60 months). Of 439 patients undergoing complete gross resection, 100 (23%) had recurrence. Five-year local recurrence–free survival (LRFS) was 69%. Eight patients died of disease, all after R2 resection.”
> “In multivariate analysis, factors associated with recurrence were extremity location, young age, and large tumor size, but not margin. Abdominal wall tumors had the best outcome (5-year LRFS 91%).”

Source: [Crago et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4096320/)

<a id="topic-2.2.2.1.2-10"></a>

### Resection margins and local recurrence across sixteen reports

> “Sixteen reports were included, consisting of a total of 1295 patients with DF. In patients treated by surgical resection alone, the risk of local recurrence was almost twofold higher for those with microscopically positive resection margins (risk ratio (RR) 1·78, 95 per cent c.i. 1·40 to 2·26).”

Source: [Janssen et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28199014/)

<a id="topic-2.2.2.1.2-11"></a>

### Recurrence and amputation after surgery reported by participants

> “Continued tumor regrowth or recurrence following any DT treatment was reported for 46% (92/202) of participants, with a higher rate post-surgery (63%, 103/163), regardless of tumor location (Fig. 4). Amputation was reported for 7% (12/163) of participants who underwent surgery, with most (83%, 10/12) experiencing tumor regrowth or recurrence post-amputation.”

Source: [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/)

<a id="topic-2.2.2.1.2-12"></a>

### Literature review of recurrence and functional deficits after surgery

> “We conducted a literature review to assess the burden of surgery in patients with DT, focusing on recurrence rates and functional deficits resulting from surgeries.”
> “Although surgery is a potential treatment option, complete excision with negative margins is not often possible, the postsurgery recurrence rate is high, and surgery can result in disfigurement and/or loss of function.”
> “Tumors in the extremities have the highest risk of recurrence (30%-90%). Lower rates of recurrences have been reported when radiotherapy was used after surgery (14%-38%).”

Source: [Fernandez et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37099290/)

## Related pages
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors.md)
- [Varegacestat (AL102) in Desmoid tumors: Terms and abbreviations](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations.md)
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary.md)
- [Varegacestat (AL102) in Desmoid tumors: Product information and disease description](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description.md)
- [Varegacestat (AL102) in Desmoid tumors: Clinical evidence](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence.md)
- [Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics.md)
- [Varegacestat (AL102) in Desmoid tumors: References](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references.md)
